Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | RORB | Q92753 | 3/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7580304 | 0.85 | CDK4 (0.40) | HPGDMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL7573156 | 0.85 | KMT2A (0.39) | HPGDMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL7581732 | 0.83 | HPGD (0.48) | HPGDMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL7580999 | 0.81 | HPGD (0.46) | HPGDMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL7574589 | 0.80 | HPGD (0.44) | HPGDMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL8783268 | 0.78 | L3MBTL1 (0.42) | HPGDMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL7572359 | 0.71 | SRC (0.45) | HPGDMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL7581747 | 0.71 | GABRP (0.54) | — | |
| SCHEMBL7581639 | 0.70 | CDK4 (0.42) | HPGDMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL8783403 | 0.70 | MEN1 (0.42) | HPGDMEN1KMT2ASMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6448265-B1 | CORTICOTROPIN RELEASING FACTOR(CRF); ANTIDEPRESSANT; (5-AMINO-1-(2,6-DICHLORO-4-TRIFLUOROMETHYLPHENYL)-3-METHYLSULFANYL-1H -PYRAZOL-4-YL)-(2,5-DIMETHYLPHENYL)METHANONE FOR EXAMPLE | PFIZER, INC. | 2002-09-10 | — | — | US | disclosed |
| US-6441018-B2 | TREATMENT OF A WIDE RANGE OF DISEASES INCLUDING STRESS-RELATED ILLNESSES. | PFIZER INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020049227-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | FARACI WILLIAM STEPHAN (US) | 2002-04-25 | — | — | US | disclosed |
| US-20020016333-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | FARACI WILLIAM STEPHEN (US) | 2002-02-07 | — | — | US | disclosed |
| EP-1062205-A2 | INHIBITORS OF PHOSPHOLIPASE ENZYMES | GENETICS INSTITUTE, INC. (US) | 2000-12-27 | — | — | EP | disclosed |
| US-6103900-A | CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST WHICH TREAT STRESS-INDUCED DISEASES | PFIZER INC (US) | 2000-08-15 | — | — | US | disclosed |
| US-6005109-A | CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY; EFFECTIVE IN THE TREATMENT OF A WIDE RANGE OF DISEASES INCLUDING STRESS-RELATED ILLNESSES | PFLIZER INC. (US) | 1999-12-21 | — | — | US | disclosed |
| WO-1999043654-A2 | INHIBITORS OF PHOSPHOLIPASE ENZYMES | GENETICS INSTITUTE, INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| EP-0674624-B1 | PYRAZOLES HAVING CRF ANTAGONIST ACTIVITY | PFIZER (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5712303-A | ANTIDEPRESSANTS | PFIZER INC. (US) | 1998-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016333-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | CRH, CRHR1, CRHR2 | HPGD 1496/4885MEN1 2637/4885KMT2A 4103/4885 |
| US-20020049227-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | CRH, CRHR1, CRHR2 | HPGD 1496/4885MEN1 2637/4885KMT2A 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.